Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Yoshihisa Kobayashi, Ph.D., M.D.

Title
Institution
Department
Address
Phone
Profile Picture

Biography
Mie University Faculty of Medicine, JapanMD03/2008
Kindai University Faculty of Medicine, JapanPhD03/2017
2017
Kindai University President’s Award
2017
Mie Medical Young Investigator Award
2016
Young Scientist Award of the Japan Lung Cancer Society
2015
Young Investigator Travel Award at 16th WCLC

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. (Yoshihisa Kobayashi) Apr 1, 2020 - Mar 31, 2021
    Uehara Memorial Foundation
    Research Fellowship from Uehara Memorial Foundation
  2. (Yoshihisa Kobayashi) Apr 1, 2018 - Mar 31, 2020
    Japan Society for the Promotion of Science
    Overseas Research Fellowships from the Japan Society for the Promotion of Science
  3. (Yoshihisa Kobayashi) Jan 1, 2017 - Dec 31, 2017
    Osaka Cancer Society
    Research grant from Osaka Cancer Society
  4. (Yoshihisa Kobayashi) Jan 1, 2017 - Dec 31, 2017
    Novartis Pharma
    Research grant from Novartis Pharma
  5. (Yoshihisa Kobayashi) Apr 1, 2016 - Mar 31, 2018
    Japan Society for the Promotion of Science
    Grant-in-Aid for Young Scientists from the Japan Society for the Promotion of Science (B) (No.16K19989)

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Cooper AJ, Kobayashi Y, Kim D, Clifford SE, Kravets S, Dahlberg SE, Chambers ES, Li J, Rangachari D, Nguyen T, Costa DB, Rabin MS, Wagle N, Sholl LM, Jänne PA, Oxnard GR. Identification of a RAS-activating TMEM87A-RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 Aug 01; 26(15):4072-4079. PMID: 32312893.
    Citations:    
  2. Kobayashi Y, Mitsudomi T. Ground glass nodules with 5 years' stability can grow after 10-year follow-up: do genetic features determine the fate? Transl Lung Cancer Res. 2019 Dec; 8(Suppl 4):S425-S427. PMID: 32038929.
    Citations:    
  3. Fujino T, Kobayashi Y, Suda K, Koga T, Nishino M, Ohara S, Chiba M, Shimoji M, Tomizawa K, Takemoto T, Mitsudomi T. Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro. J Thorac Oncol. 2019 10; 14(10):1753-1765. PMID: 31279006.
    Citations:    
  4. Ohara S, Tomizawa K, Shimizu S, Suda K, Fujino T, Hamada A, Koga T, Nishino M, Kobayashi Y, Sato K, Chiba M, Shimoji M, Takemoto T, Soh J, Mitsudomi T. Primary pulmonary mucosa-associated lymphoid tissue lymphoma with amyloid light chain-type amyloidosis. Surg Case Rep. 2019 Jun 26; 5(1):105. PMID: 31243589.
    Citations:    
  5. Tomizawa K, Sato K, Ohara S, Fujino T, Koga T, Nishino M, Kobayashi Y, Chiba M, Shimoji M, Suda K, Takemoto T, Mitsudomi T. Life-threatening complications after pulmonary resection for lung cancer in patients on chronic hemodialysis. Surg Today. 2019 Jun; 49(6):513-520. PMID: 30706240.
    Citations:    
  6. Yonesaka K, Kobayashi Y, Hayashi H, Chiba Y, Mitsudomi T, Nakagawa K. Dual blockade of EGFR tyrosine kinase using osimertinib and afatinib eradicates EGFR-mutant Ba/F3 cells. Oncol Rep. 2019 Feb; 41(2):1059-1066. PMID: 30483795.
    Citations:    
  7. Nishino M, Suda K, Kobayashi Y, Ohara S, Fujino T, Koga T, Chiba M, Shimoji M, Tomizawa K, Takemoto T, Mitsudomi T. Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro. Lung Cancer. 2018 12; 126:149-155. PMID: 30527179.
    Citations:    
  8. Koga T, Kobayashi Y, Tomizawa K, Suda K, Kosaka T, Sesumi Y, Fujino T, Nishino M, Ohara S, Chiba M, Shimoji M, Takemoto T, Suzuki M, Jänne PA, Mitsudomi T. Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study. Lung Cancer. 2018 12; 126:72-79. PMID: 30527195.
    Citations:    
  9. Kobayashi Y, Ambrogio C, Mitsudomi T. Ground-glass nodules of the lung in never-smokers and smokers: clinical and genetic insights. Transl Lung Cancer Res. 2018 Aug; 7(4):487-497. PMID: 30225212.
    Citations:    
  10. Kobayashi Y, Fujino T, Nishino M, Koga T, Chiba M, Sesumi Y, Ohara S, Shimoji M, Tomizawa K, Takemoto T, Mitsudomi T. EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib. J Thorac Oncol. 2018 05; 13(5):727-731. PMID: 29410323.
    Citations:    
  11. Nishino M, Tomizawa K, Ohara S, Fujino T, Sesumi Y, Koga T, Sato K, Kobayashi Y, Chiba M, Shimoji M, Takemoto T, Mitsudomi T. [A Case of Resected Superior Sulcus Tumor with Pathological Complete Response after Trimodality Therapy]. Gan To Kagaku Ryoho. 2018 Jan; 45(1):103-105. PMID: 29362322.
    Citations:    
  12. Tomizawa K, Shimizu S, Ohara S, Fujino T, Nishino M, Sesumi Y, Kobayashi Y, Sato K, Chiba M, Shimoji M, Suda K, Takemoto T, Mitsudomi T. Clinical significance of tumor cavitation in surgically resected early-stage primary lung cancer. Lung Cancer. 2017 10; 112:57-61. PMID: 29191601.
    Citations:    
  13. Chiba M, Togashi Y, Bannno E, Kobayashi Y, Nakamura Y, Hayashi H, Terashima M, De Velasco MA, Sakai K, Fujita Y, Mitsudomi T, Nishio K. Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A. BMC Cancer. 2017 04 19; 17(1):281. PMID: 28424065.
    Citations:    
  14. Sesumi Y, Suda K, Mizuuchi H, Kobayashi Y, Sato K, Chiba M, Shimoji M, Tomizawa K, Takemoto T, Mitsudomi T. Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells. Lung Cancer. 2017 02; 104:85-90. PMID: 28213007.
    Citations:    
  15. Kobayashi Y, Azuma K, Nagai H, Kim YH, Togashi Y, Sesumi Y, Chiba M, Shimoji M, Sato K, Tomizawa K, Takemoto T, Nishio K, Mitsudomi T. Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer. Mol Cancer Ther. 2017 02; 16(2):357-364. PMID: 27913578.
    Citations:    
  16. Tomizawa K, Nishino M, Sesumi Y, Kobayashi Y, Sato K, Chiba M, Shimoji M, Suda K, Shimizu S, Sato T, Takemoto T, Mitsudomi T. Prognostic impact of pleural lavage cytology in patients with primary lung cancer. Lung Cancer. 2016 12; 102:60-64. PMID: 27987590.
    Citations:    
  17. Park J, Kobayashi Y, Urayama KY, Yamaura H, Yatabe Y, Hida T. Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma. PLoS One. 2016; 11(8):e0161081. PMID: 27518729.
    Citations:    
  18. Kobayashi Y, Mitsudomi T. Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy. Cancer Sci. 2016 Sep; 107(9):1179-86. PMID: 27323238.
    Citations:    
  19. Mitsudomi T, Kobayashi Y. Afatinib in lung cancer harboring EGFR mutation in the LUX-Lung trials: six plus three is greater than seven? Transl Lung Cancer Res. 2016 Aug; 5(4):446-9. PMID: 27650363.
    Citations:    
  20. Banno E, Togashi Y, Nakamura Y, Chiba M, Kobayashi Y, Hayashi H, Terashima M, de Velasco MA, Sakai K, Fujita Y, Mitsudomi T, Nishio K. Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor? Cancer Sci. 2016 Aug; 107(8):1134-40. PMID: 27240419.
    Citations:    
  21. Shimoji M, Shimizu S, Sato K, Suda K, Kobayashi Y, Tomizawa K, Takemoto T, Mitsudomi T. Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1). Lung Cancer. 2016 08; 98:69-75. PMID: 27393509.
    Citations:    
  22. Mizuuchi H, Suda K, Murakami I, Sakai K, Sato K, Kobayashi Y, Shimoji M, Chiba M, Sesumi Y, Tomizawa K, Takemoto T, Sekido Y, Nishio K, Mitsudomi T. Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer. Cancer Sci. 2016 Apr; 107(4):461-8. PMID: 26845230.
    Citations:    
  23. Kobayashi Y, Togashi Y, Yatabe Y, Mizuuchi H, Jangchul P, Kondo C, Shimoji M, Sato K, Suda K, Tomizawa K, Takemoto T, Hida T, Nishio K, Mitsudomi T. EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs. Clin Cancer Res. 2015 Dec 01; 21(23):5305-13. PMID: 26206867.
    Citations:    
  24. Togashi Y, Mizuuchi H, Kobayashi Y, Hayashi H, Terashima M, Sakai K, Banno E, Mizukami T, Nakamura Y, de Velasco MA, Fujita Y, Tomida S, Mitsudomi T, Nishio K. An activating ALK gene mutation in ALK IHC-positive/FISH-negative nonsmall-cell lung cancer. Ann Oncol. 2015 Aug; 26(8):1800-1. PMID: 26002608.
    Citations:    
  25. Mizuuchi H, Suda K, Sato K, Tomida S, Fujita Y, Kobayashi Y, Maehara Y, Sekido Y, Nishio K, Mitsudomi T. Collateral chemoresistance to anti-microtubule agents in a lung cancer cell line with acquired resistance to erlotinib. PLoS One. 2015; 10(4):e0123901. PMID: 25875914.
    Citations:    
  26. Banno E, Togashi Y, Kobayashi Y, Hayashi H, Mitsudomi T, Nishio K. Afatinib is especially effective against non-small cell lung cancer carrying an EGFR exon 19 deletion. Anticancer Res. 2015 Apr; 35(4):2005-8. PMID: 25862853.
    Citations:    
  27. Kobayashi Y, Mitsudomi T, Sakao Y, Yatabe Y. Genetic features of pulmonary adenocarcinoma presenting with ground-glass nodules: the differences between nodules with and without growth. Ann Oncol. 2015 Jan; 26(1):156-161. PMID: 25361983.
    Citations:    
  28. Suda K, Sato K, Mizuuchi H, Kobayashi Y, Shimoji M, Tomizawa K, Takemoto T, Iwasaki T, Sakaguchi M, Mitsudomi T. Recent evidence, advances, and current practices in surgical treatment of lung cancer. Respir Investig. 2014 Nov; 52(6):322-9. PMID: 25453375.
    Citations: 4     Fields:    Translation:Humans
  29. Kobayashi Y, Nakada J, Kuroda H, Sakakura N, Usami N, Sakao Y. Spinal epidural hematoma during anticoagulant therapy for pulmonary embolism: postoperative complications in a patient with lung cancer. Ann Thorac Cardiovasc Surg. 2014; 20 Suppl:493-6. PMID: 24492175.
    Citations:    
  30. Park J, Yamaura H, Yatabe Y, Hosoda W, Kondo C, Shimizu J, Horio Y, Yoshida K, Tanaka K, Oguri T, Kobayashi Y, Hida T. Anaplastic lymphoma kinase gene rearrangements in patients with advanced-stage non-small-cell lung cancer: CT characteristics and response to chemotherapy. Cancer Med. 2014 Feb; 3(1):118-23. PMID: 24403104.
    Citations:    
  31. Kobayashi Y, Sakao Y, Deshpande GA, Fukui T, Mizuno T, Kuroda H, Sakakura N, Usami N, Yatabe Y, Mitsudomi T. The association between baseline clinical-radiological characteristics and growth of pulmonary nodules with ground-glass opacity. Lung Cancer. 2014 Jan; 83(1):61-6. PMID: 24268684.
    Citations:    
  32. Kobayashi Y, Mitsudomi T. Management of ground-glass opacities: should all pulmonary lesions with ground-glass opacity be surgically resected? Transl Lung Cancer Res. 2013 Oct; 2(5):354-63. PMID: 25806254.
    Citations:    
  33. Kobayashi Y, Sakao Y, Ito S, Park J, Kuroda H, Sakakura N, Usami N, Mitsudomi T, Yatabe Y. Transformation to sarcomatoid carcinoma in ALK-rearranged adenocarcinoma, which developed acquired resistance to crizotinib and received subsequent chemotherapies. J Thorac Oncol. 2013 Aug; 8(8):e75-8. PMID: 23857406.
    Citations:    
  34. Kobayashi Y, Fukui T, Ito S, Usami N, Hatooka S, Yatabe Y, Mitsudomi T. How long should small lung lesions of ground-glass opacity be followed? J Thorac Oncol. 2013 Mar; 8(3):309-14. PMID: 23399958.
    Citations:    
  35. Kobayashi Y, Fukui T, Ito S, Shitara K, Ito S, Hatooka S, Mitsudomi T. Pulmonary metastasectomy for gastric cancer: a 13-year single-institution experience. Surg Today. 2013 Dec; 43(12):1382-9. PMID: 23184359.
    Citations:    
  36. Fukui T, Yatabe Y, Kobayashi Y, Tomizawa K, Ito S, Hatooka S, Matsuo K, Mitsudomi T. Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene. Lung Cancer. 2012 Aug; 77(2):319-25. PMID: 22483782.
    Citations:    
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Kobayashi's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (134)
Explore
_
Co-Authors (7)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.